NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call - KSWO, Lawton, OK- Wichita Falls, TX: News, Weather, Sports. ABC, 24/7, Telemundo -

NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE NewLink Genetics Corporation

AMES, Iowa, Feb. 25, 2013 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results will be released before the market opens on Thursday, February 28, 2013.  The NewLink management team will host a conference call discussing the company's financial results and recent corporate developments on Thursday, February 28, 2013, at 10:00am EST.  The call can be accessed by dialing 1-(877) 363-5052 (domestic) or 1-(914) 495-8600 (international) five minutes prior to the start of the call and providing the passcode 16064630.  A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-(855) 859-2056 (domestic) or 1-(404) 537-3406 (international), providing the passcode 16064630.  The replay will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the NewLink website at http://investors.linkp.com/.  A replay of the webcast will be archived on the company's website for two weeks following the call.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.  NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications.

Contacts:  
Gordon Link  
Chief Financial Officer   
NewLink Genetics  
1.515.598.2925  
glink@linkp.com   

©2012 PR Newswire. All Rights Reserved.